Quick answers
- What is Rifapentine used for?
- The FDA-approved label (Priftin, sanofi-aventis U.S. LLC, February 6, 2026) says: “PRIFTIN is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible. PRIFTIN is indicated for the treatment of latent tuberculosis infection (LTBI) caused by M. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Rifapentine have a boxed warning?
- No. None of the 2 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Rifapentine?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Rifapentine been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Rifapentine?
- 2 companies list prescription products of Rifapentine in the FDA NDC Directory, including Macleods Pharmaceuticals Limited and Sanofi-Aventis U.S. LLC.
What Rifapentine is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
PRIFTIN is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible. PRIFTIN is indicated for the treatment of latent tuberculosis infection (LTBI) caused by M. …
— FDA label: Priftin, sanofi-aventis U.S. LLC, effective February 6, 2026. Read the full label on DailyMed →
The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 2 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet, film coated |
|---|---|
| Route | Oral |
| Prescription products | 2 in the FDA NDC Directory |
| Brand names | Priftin |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| rifapentine 150 mg tablet, film coated | Brand: Priftin | $4.83 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Macleods Pharmaceuticals Limited1 product
- Sanofi-Aventis U.S. LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021024 PRIFTIN | Sanofi Aventis Us | June 22, 1998 | 16, latest January 27, 2026 2026: Labeling · 2020: Labeling · 2020: Labeling |
Generic approvals (1)
- ANDA217042Macleods Pharms · June 23, 2026
Shortage status
Shortage resolved · updated August 6, 2026 · first posted March 25, 2020
| Product | Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24) |
|---|---|
| Company | Sanofi-Aventis U.S. LLC |
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 242671, 261101 |
|---|---|
| SPL set ID of the quoted label | 3a64fb70-b85e-43d9-8bcd-7e893f568ae1 |
| FDA labels (SPL) | 2 |
| FDA applications | NDA021024, 1 ANDA |
| Active ingredients (FDA) | RIFAPENTINE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Priftin, sanofi-aventis U.S. LLC, effective February 6, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →